Thus, the assessment of PD-L1 status in lung cancer has been of significant interest and supported by several studies which demonstrate that cancers with ≥50% PD-L1 expression respond very well to PD-1/PD-l1 targeted therapies [20,21,22,40]. The gene discussed is PDCD1; the disease is lung carcinoma.